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An overview of miRNAs altered in Alzheimer’s disease (AD) was established by
profiling the hippocampus of a cohort of 41 late-onset AD (LOAD) patients and
23 controls, showing deregulation of 35 miRNAs. Profiling of miRNAs in the
prefrontal cortex of a second independent cohort of 49 patients grouped by
Braak stages revealed 41 deregulatedmiRNAs. We focused onmiR-132-3p which
is strongly altered in both brain areas. Downregulation of this miRNA occurs
already at Braak stages III and IV, before loss of neuron-specific miRNAs. Next-
generation sequencing confirmed a strong decrease of miR-132-3p and of three
family-related miRNAs encoded by the same miRNA cluster on chromosome 17.
Deregulation of miR-132-3p in AD brain appears to occur mainly in neurons
displaying Tau hyper-phosphorylation. We provide evidence that miR-132-3p
may contribute to disease progression through aberrant regulation of mRNA
targets in the Tau network. The transcription factor (TF) FOXO1a appears to be a
key target of miR-132-3p in this pathway.
INTRODUCTION
Alzheimer’s disease (AD) is a progressive age‐related dementia
characterized by amyloid plaques, neuronal tangles, neurofi-
brillary degeneration and vascular amyloidopathy in the brain.
The cause of early‐onset AD (EOAD) is well known with
mutations in the APP, PSEN1 and PSEN2 genes, contributing to
the accumulation of amyloid plaques. In late‐onset AD (LOAD),
genome‐wide association studies (GWAS) recently identified
more than ten other loci [reviewed in (Tanzi, 2012)], suggesting
the existence of additional molecular pathways contributing to
the disease. MicroRNAs (miRNAs) are short 22 nt RNA
molecules that bind to the transcripts of protein‐coding genes to
direct their post‐transcriptional repression and by that regulate
important physiological and pathophysiological signalling
pathways. Increasing evidence links aberrant expression of
miRNAs to neurodegenerative disorders including AD
[reviewed in (Lau & de Strooper, 2010)]. For instance, miR‐
29b was found to be downregulated in the anterior temporal
cortex of a subgroup of AD patients with high BACE1 protein
expression (Hebert et al, 2008) and decreased miR‐107 was also
observed in the temporal cortex of some AD cases (Wang et al,
2008). However, the small number of patients analyzed
represents a major issue when identifying which miRNAs are
deregulated during disease. Confounding factors, in particular
the technologies used for miRNA profiling which provide
deviating results (Pritchard et al, 2012), have to be considered
as well.
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A more systematic analysis of miRNAs is clearly needed to
determine which miRNAs and molecular networks normally
controlled by such miRNAs are affected during disease
[reviewed in (Salta & De Strooper, 2012)]. We aimed here to
determinemiRNA alterations in LOAD by profiling two large and
independent cohorts of patients using the nCounter system, a
technology proven to reliably quantify miRNAs (Wyman et al,
2011). We found numerous changes in the expression of
miRNAs in the hippocampus and prefrontal cortex of LOAD
patients. Of importance, downregulation of miR‐132‐3p stands
out by robustness and consistency. This observation was
confirmed by real‐time PCR on the two same brain areas
initially investigated and for the temporal gyrus. In agreement,
downregulation of miR‐132‐3p in the LOAD prefrontal cortex
was also found by next‐generation sequencing of miRNAs and
by in situ hybridization. We also provide initial identification of
miR‐132‐3p targets of relevance to LOAD, thus offering novel
insights into the pathogenesis of the disease.
RESULTS
Deregulation of miRNAs in the hippocampus of LOAD patients
We analyzed themiRNA expression profile of a first cohort made
of 41 LOAD cases and 23 age‐matched controls (clinical data in
Supporting Information Table S1). The quality of the total RNA
obtained from these post‐mortem samples was systematically
assessed (Supporting Information Fig S1A). The RNA Integrity
Number (RIN) values were relatively low, indicating fragmented
total RNA. However, raw data analysis showed that global
expression of miRNAs in the samples with lower (2<RIN< 6)
and higher RIN values (RIN> 6) was similar (Supporting
Information Figs S1B and S2A), therefore indicating that miRNAs
were relatively resistant to RNA degradation. Because of the
discrete counting nature of the nCounter system used for miRNA
profiling, positive skewness (Supporting Information Fig S2B)
and overdispersion of the data (Supporting Information Fig S3B),
a statistical model based on the negative binomial distribution as
implemented in the DESeq package (Anders & Huber, 2010) was
used to call differential miRNA expression. We found that 35
(5.5%) of 641 tested miRNAs were differentially expressed
between the LOAD cases and the control group [padj< 0.05,
nbinomTest corrected for multiple testing by the Benjamini–
Hochberg (BH) procedure]. Of interest, 20 miRNAs were
downregulated and 15 were upregulated in the LOAD group
when compared to the controls (Table 1 and Fig 1A). Notably,
we identified miR‐132‐3p as the most significantly down-
regulated miRNA (padj¼ 1.57E07) together with other brain‐
enriched miRNAs such as miR‐128, miR‐136‐5p, miR‐138‐5p,
miR‐124‐3p, miR‐129‐5p and miR‐129‐2‐3p. Among the upregu-
lated miRNAs in the LOAD group and with previous reported
expression in the brain, we found miR‐27a‐3p, miR‐142‐3p, miR‐
92b‐3p and miR‐200a‐3p (Table 1 and Fig 1A).
A supervised clustering based on Support Vector Machine
(SVM) was built to evaluate whether the 35 differentially
expressed miRNAs could be used to classify the hippocampus
samples. After trainingwith a subset consisting of 10 LOAD cases
and 10 controls, the SVM classifier was tested on the 44
remaining samples including 31 LOAD cases and 13 controls.
Among the 44 samples, three (X7H, X27H, X30H) LOAD cases
were misclassified as controls whereas all the control samples
were correctly assigned, resulting in a sensitivity of 90% and a
specificity of 100% for this assay (Fig 1B). The receiver operating
characteristic (ROC) curve further showed an area under the
curve (AUC) of 0.96 (Fig 1C), confirming the potential
application of these 35 miRNAs as markers of LOAD.
Temporal analysis of miRNAs in the prefrontal cortex of LOAD
patients
We next studied 49 prefrontal cortex samples from a second
cohort of clinically well‐defined patients stratified according to
the six classical Braak stages (BRI to VI) and of seven control
samples (BR0) (clinical data in Supporting Information Table S2)
(Bossers et al, 2010). The global cellular composition in this
brain area remains well preserved over different Braak stages in
comparison to the hippocampus.
Quality assessment showed excellent total RNA integrity for
those samples when compared to those in the first cohort studied
(Supporting Information Fig S1A). Global expression profile of
miRNAs for the 49 prefrontal cortex samples was similar,
irrespective of the Braak stages and of the quality of the RNA
(Supporting Information Fig S1C). Skewness and overdispersion of
the nCounter data were observed (Supporting Information Fig S3A
and C). We therefore applied a general linear model (GLM) based
on the negative binomial distribution to find differentially
expressed miRNAs between any two Braak stages. In total, 41
(6.4%) of 641 tested miRNAs were found to be changed
(padj< 0.05, nbinomGLMTest after BH correction) (Table 2 and
Fig 2A). The expression analysis of those 41 significantly altered
miRNAs showed dynamic expression patterns that were charac-
teristic of downregulated (clusters 1, 2 and 3) and upregulated
(cluster 4) miRNAs (Fig 2B). Of importance, some of the miRNA
changes were observed at early BRI and BRII stages. For instance,
the eight miRNAs in cluster 1, including miR‐132‐3p, were
upregulated between BRI and BRII, and then downregulated
between BRII and BRVI. Cluster 2 was mainly characterized by a
small loss between BRII and BRIV, followed by a steep decline
between late BRV and BRVI stages. Eleven miRNAs such as miR‐
129‐5p,miR‐129‐2‐3p,miR‐136‐5p,miR‐370,miR‐409‐5p andmiR‐
487a belong to this cluster 2. Cluster 3 consisted of 10 miRNAs
showing a gradual downregulation between BR0/BRI and BRVI.
Lastly, cluster 4 wasmade of 12 upregulatedmiRNAs such as miR‐
27a‐3p, miR‐92b‐3p and miR‐200a‐3p. The complete list of
miRNAs in each of the four clusters is included in Table 2. In
addition, a comparison of miRNAs found to be deregulated
between any two Braak stages by the nbinomGLMTest imple-
mented in DESeq to those found by two other popular algorithms,
i.e. edgeR and VoomþLimma, shows that 40 of 41miRNAs found
to be changed in the prefrontal cortex byDESeqwere also called by
at least one of the two other methods (Supporting Information
Fig S4), therefore supporting the robustness of the analysis.
To assess to what extent differences in miRNAs could be
explained by changes in the cell types over the disease, we
analyzed the prefrontal cortex expression of miRNAs previously
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shown to be enriched in rodent neurons, astrocytes, oligoden-
drocytes and microglia, respectively (Jovicic et al, 2013; Lau
et al, 2008). Neuron‐enriched miRNAs were miR‐124‐3p, miR‐
127‐3p, miR‐128, miR‐129‐2‐3p, miR‐129‐5p, miR‐136‐5p, miR‐
376a‐3p and miR‐495‐3p. Of interest, downregulation of those
neuronal miRNA markers was evident between BRV and BRVI
stages (Fig 2C), supporting the idea of some neuronal loss at late
stages of disease. In contrast, microglial‐enriched miR‐142‐3p,
miR‐142‐5p, miR‐146a‐5p, miR‐150‐5p and miR‐223‐3p were
increased at late BRV and BRVI stages (Fig 2C). For
oligodendrocytes, we recorded the level of miR‐219‐2‐3p/miR‐
219‐5p and the expression of miR‐31‐5p and miR‐143‐3p was
monitored for astrocytes. Again, the oligodendrocyte‐enriched
miRNAs were increased between BRV and BRVI stages but no
clear trend was found for the two astrocyte‐enriched miRNAs
(Fig 2C). More importantly, and in contrast to the late loss of
neuronal miRNA markers, downregulation of miR‐132‐3p was
remarkably strong at early and mid‐stages of disease already.
This difference in miR‐132‐3p expression was more pronounced
than what was found for the other neuronal miRNAs, clearly
indicating that downregulation of miR‐132‐3p cannot be
explained by simple cell loss (Fig 2C, indicated by arrow).
Overall, it seems likely that miRNAs that are already changing at
early and mid Braak stages are linked to the disease process itself
Table 1. Deregulated miRNAs in the hippocampus of LOAD patients
miRNA Control LOAD Fold Change log2 Fold Change pval padj
hsa-miR-132-3p 4316 2541 0.59 0.76 6.35E-10 1.57E-07
hsa-miR-128 3995 2443 0.61 0.71 1.42E-07 1.76E-05
hsa-miR-23a-3p 1207 1876 1.55 0.64 1.44E-05 0.0011903
hsa-miR-455-5p 14 40 2.95 1.56 2.72E-05 0.0016864
hsa-miR-129-5p 539 346 0.64 0.64 3.51E-05 0.0017411
hsa-miR-363-3p 157 251 1.60 0.68 5.96E-05 0.0024648
hsa-miR-27a-3p 129 215 1.67 0.74 0.0001669 0.0059128
hsa-miR-370 92 51 0.55 0.85 0.0002451 0.0067535
hsa-miR-487b 1860 1321 0.71 0.49 0.0002444 0.0067535
hsa-let-7f-5p 4040 5712 1.41 0.50 0.0002978 0.0072293
hsa-miR-223-3p 613 885 1.44 0.53 0.0003366 0.0072293
hsa-miR-433 330 213 0.65 0.63 0.0003498 0.0072293
hsa-miR-195-5p 590 843 1.43 0.51 0.0004041 0.0077096
hsa-miR-138-5p 130 80 0.62 0.70 0.0004766 0.008442
hsa-miR-142-3p 821 1358 1.66 0.73 0.0005951 0.0098391
hsa-miR-129-2-3p 2245 1606 0.72 0.48 0.0007848 0.0117644
hsa-miR-150-5p 463 664 1.43 0.52 0.0008064 0.0117644
hsa-miR-136-5p 1534 1135 0.74 0.43 0.0012255 0.0168841
hsa-let-7i-5p 3802 5118 1.35 0.43 0.0014724 0.0175449
hsa-miR-124-3p 306 205 0.67 0.58 0.0014857 0.0175449
hsa-miR-362-3p 98 151 1.54 0.62 0.001356 0.0175449
hsa-miR-92b-3p 1060 1529 1.44 0.53 0.0016005 0.0180415
hsa-miR-127-3p 346 239 0.69 0.54 0.0017286 0.0186383
hsa-miR-329 240 160 0.67 0.58 0.0019822 0.0196638
hsa-miR-495-3p 1946 1454 0.75 0.42 0.0019607 0.0196638
hsa-miR-409-5p 46 25 0.53 0.92 0.0021989 0.0209741
hsa-miR-487a 506 369 0.73 0.45 0.0026776 0.0245943
hsa-miR-410 647 481 0.74 0.43 0.0028013 0.0248112
hsa-miR-543 432 316 0.73 0.45 0.0040771 0.034866
hsa-miR-199a-3p 88 138 1.57 0.65 0.0048687 0.0389497
hsa-miR-199b-3p 88 138 1.57 0.65 0.0048687 0.0389497
hsa-miR-769-5p 47 27 0.57 0.81 0.0053295 0.0413038
hsa-miR-219-2-3p 2244 1711 0.76 0.39 0.0060143 0.0443437
hsa-miR-425-5p 147 98 0.67 0.58 0.0060794 0.0443437
hsa-miR-200a-3p 53 103 1.94 0.96 0.0067664 0.0479449
The name of the mature miRNAs is in accordance with the miRBase V19 nomenclature. Control: normalized counts for the control group; LOAD: normalized
counts for the LOAD group; Fold Change and log2 Fold Change correspond to the difference between the LOAD and Control groups; pval: nominal p-value
determined by the nbinomTest; padj: nominal p-value corrected for multiple testing by the BH procedure.
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rather than being the result of simple alterations in cellular
composition of the diseased brain, as this would have been
reflected inmuchmore dramatic expression changes of cell‐type‐
enriched miRNAs.
Because our main goal was to reliably identify individual
miRNAs deregulated in the disease, we merged the hippocam-
pus and prefrontal cortex data to obtain a ‘high‐confidence’ list
of miRNAs changed in these two brain areas. Although a vast
Figure 1.
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majority of the 66 unique miRNA alterations appeared to be
specific to one of the two brain regions investigated, an overlap
of 10 miRNAs including miR‐132‐3p, miR‐129‐5p, miR‐27a‐3p,
miR‐92b‐3p, miR‐129‐2‐3p, miR‐136‐5p, miR‐200a‐3p, miR‐370,
miR‐409‐5p and miR‐487a was found.
Deregulation of miR‐132‐3p in the hippocampus, prefrontal
cortex and temporal gyrus of LOAD patients
The 10 miRNAs from the ‘high‐confidence’ list were selected for
technical validation by real‐time PCR on the hippocampus of five
LOAD cases (X1H, X14H, X29H, X32H, X9H) and five controls
(X49H, X52H, X53H, X71H, X144H). We confirmed the
upregulation of miR‐92b‐3p (padj< 0.05, ANOVA corrected
for multiple testing by the BH procedure) and downregulation of
miR‐129‐2‐3p, miR‐129‐5p, miR‐132‐3p, miR‐136‐5p, miR‐370,
miR‐409‐5p and miR‐487a in the five LOAD cases when
compared to the control group (Fig 3A). Similarly to the
nCounter data, miR‐132‐3p was the most significantly altered
miRNA (padj¼ 2.88E04). However, we did not confirm changes
in the expression of miR‐200a‐3p (padj¼ 0.22) nor miR‐27a‐3p
(padj¼ 0.90) (Fig 3A), therefore eight of 10 selected miRNAs
were firmly validated by two assays.
For the prefrontal cortex samples, real‐time PCR was
performed for the 10 selected miRNAs on a first group consisting
of four controls and two early‐stages samples (BR0.2, BR0.4,
BR0.5, BR0.7, BR1.2, BR1.3) and on a second group of six late‐
stages brain samples (BR5.7, BR6.2, BR6.3, BR6.4, BR6.5,
BR6.7). Similar to the PCR validation of the hippocampus
samples, we confirmed miR‐132‐3p as the most significantly
downregulatedmiRNA in the prefrontal cortex (padj¼ 1.23E03)
(Fig 3B). In addition, miR‐129‐5p and miR‐136‐5p were also
found to be differentially expressed, resulting in the validation of
only three out of 10 miRNAs (Fig 3B). Such difference in the
results, pending on sampling and/or techniques used, is an
acknowledged concern in the field (Pritchard et al, 2012).
In addition to the hippocampus and prefrontal cortex areas,
we aimed at biologically confirming the deregulation of the 10
miRNAs in a third brain region affected in LOAD. Real‐time PCR
was therefore performed on the temporal gyrus of a third cohort
of eight LOAD individuals (five BRV and three BRVI patients)
and eight apparently healthy individuals corresponding to non‐
demented cases (one BR0 and seven BRI subjects) (clinical data
in Supporting Information Table S3). There was no difference
between the two groups for miR‐129‐5p, miR‐136‐5p and seven
othermiRNAs from the ‘high‐confidence’ list (Fig 3C). Obviously
those miRNA changes were only seen in specific brain areas or
picked by particular techniques, implying the importance of
using orthogonal techniques when studying miRNA expression.
However, we observed for a third time a significant down-
regulation of miR‐132‐3p (padj¼ 0.02) (Fig 3C). Overall, miR‐
132‐3p was found to be downregulated in three different LOAD
brain areas of three cohorts of patients using two different
technologies, making this observation highly reproducible and
robust.
We determined whether miR‐132‐3p deregulation in LOAD
was the direct result of the inflammatory component of the
disease by profiling its expression in another brain disorder
characterized by neuroinflammation, i.e. multiple sclerosis
(MS). Real‐time PCR of the white matter of eight control
subjects was compared to that of six MS samples with confirmed
neuroinflammatory process (active lesions) and matched
chronic lesions. We found that miR‐132‐3p was not differentially
expressed between active lesions and controls (p¼ 0.83, post hoc
Tukey’s after ANOVA corrected for multiple testing by the BH
procedure) nor between chronic lesions and controls (padj
¼ 0.10) (Fig 3D). Additionally, we found higher levels of miR‐
129‐5p and miR‐370 in the active and chronic lesions when
compared to the controls (padj< 0.05). More specifically,
downregulation of miR‐92b‐3p and miR‐136‐5p was only
observed between chronic lesions and controls (Fig 3D).
Overall, these data show that LOAD and MS share some altered
miRNAs, but not miR‐132‐3p, therefore suggesting that
deregulation of this miRNA in LOAD is unlikely a direct
consequence of a general inflammatory process.
Deep‐sequencing of miRNAs in the LOAD prefrontal cortex
confirms the deregulation of miR‐132‐3p
The nCounter system used in our study turns out to have two
major drawbacks. First, it covers only 641well‐expressed human
miRNAs but not all the 2038 miRNAs found in the current
3 Figure 1. Differential expression of miRNAs in late‐onset AD (LOAD) hippocampus.
A. Hierarchical clustering of deregulated miRNAs. Thirty-five significant miRNAs (p<0.05, nbinomTest after BH adjustment) obtained from 64 hippocampus
samples were hierarchically clustered using Spearman’s correlation. Horizontal bar above the heatmap indicates the control (green) and LOAD (red) groups as
defined by pathologic examination. The sample identifiers are indicated at the bottom of the heatmap and miRNAs are found on the right side. Blue colour
corresponds to low miRNA expression values and red denotes high expression values as indicated by the colour key.
B. Probability prediction of the hippocampus samples. The Support Vector Machine (SVM) training algorithm was built on a subset of 10 LOAD and 10 controls
considering the 35 differentially expressed miRNAs shown in panel A. The obtained predictors were used to test the remaining 31 LOAD cases and 13 control
samples. The index corresponds to each patient and the vertical dashed line delineates the control (left) and LOAD (right) groups. The y-axis represents the
probability of diagnosis for each of the samples as determined by the SVM classifier (predicted class). Blue and red dots correspond to the probability that the
sample belongs to the control group or the LOAD group, respectively. A sample is considered as misclassified when the probability for the predicted class is
higher than and different from the probability corresponding to the real class (as defined by clinical diagnosis). By using this binary SVM classifier, three LOAD
samples were misclassified as controls and all the controls were correctly called.
C. Receiver operating characteristic (ROC) curve of the hippocampus-derived SVM classifier. The ROC curve summarizes the accuracy of the SVM built on the 35
differentially expressed miRNAs using a number of cross-validation equals to the number of predictions (n¼44). This set of miRNAs was predictive of
LOAD with a sensitivity of 90% and a specificity of 100%. The area under the curve (AUC) was 0.96, with the best possible value would be one and any non-
random prediction would be more than 0.5. Following standard convention, the true positive rate is defined as sensitivity and the false positive rate as (1-
specificity).
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version of miRBase (V19, August 2012). Moreover, RNA editing
can modify the sequence of miRNAs and the nCounter system
would have not detected such editing events. To address these
two major issues, we expanded our initial profiling experiments
by deep‐sequencing miRNAs in the 12 prefrontal cortex samples
previously used for real‐time PCR validation. After lowering the
stringency of detection to find miRNAs expressed at very low
level (cut‐off of 30 counts across the 12 libraries), 839 of 2038
miRNAs were called present with 85 of them differentially
expressed between the two groups (padj< 0.001, nbinomTest
corrected for multiple testing by the BH procedure) (Table 3).
There were 50 and 35 miRNAs found to be, respectively, down
and upregulated between LOAD subjects and controls (Fig 4A
and B). Among those 85 miRNAs, 22 of themwere not present in
Table 2. Deregulated miRNAs in the prefrontal cortex of LOAD patients
miRNA BR0 BRI BRII BRIII BRIV BRV BRVI pval padj Cluster
hsa-miR-132-3p 6405 5518 7889 5638 3387 3367 2409 7.377E-12 2.279E-09 1
hsa-miR-127-5p 34 27 30 20 15 18 0 2.882E-10 3.98E-08 3
hsa-miR-1321 16 11 25 8 0 2 2 3.864E-10 3.98E-08 1
hsa-miR-210 19 38 22 28 8 5 0 6.376E-08 4.925E-06 3
hsa-miR-214-3p 82 80 24 134 116 144 266 6.686E-07 4.132E-05 4
hsa-miR-496 36 36 41 36 21 31 5 3.796E-06 0.0001955 2
hsa-miR-1178-3p 20 19 16 5 15 7 0 2.605E-05 0.0010853 3
hsa-miR-133b 18 13 21 6 3 7 1 2.968E-05 0.0010853 1
hsa-miR-337-3p 47 52 51 42 54 32 11 3.161E-05 0.0010853 2
hsa-miR-421 40 39 51 40 21 21 10 4.078E-05 0.0012602 1
hsa-miR-548j 26 20 16 15 9 11 1 0.0001314 0.0036922 3
hsa-miR-200a-3p 220 184 156 264 262 299 487 0.0001487 0.0038301 4
hsa-miR-431-5p 30 35 44 25 20 34 7 0.000173 0.0041117 2
hsa-miR-744-5p 187 173 141 246 225 234 326 0.0002172 0.004794 4
hsa-miR-491-3p 23 26 21 11 15 15 2 0.0002616 0.0053892 3
hsa-miR-633 48 42 137 10 3 15 1 0.0003924 0.0075776 1
hsa-miR-485-5p 43 45 41 28 24 38 10 0.0004575 0.0078541 3
hsa-miR-508-3p 17 18 23 14 9 8 1 0.0004413 0.0078541 1
hsa-miR-1275 32 22 5 36 28 26 33 0.0005612 0.0091191 4
hsa-miR-520a-3p 18 20 12 5 5 5 2 0.0006197 0.0091191 3
hsa-miR-758-3p 36 31 28 24 22 14 6 0.0006192 0.0091191 3
hsa-miR-135b-5p 77 80 77 71 60 59 27 0.0006627 0.0093078 2
hsa-miR-1179 23 17 29 15 10 10 2 0.000704 0.0094586 1
hsa-miR-1260a 3320 3175 2392 4873 4274 4708 6518 0.0007804 0.0100482 4
hsa-miR-551b-3p 43 63 41 36 37 25 12 0.0012518 0.0154719 3
hsa-miR-10b-5p 18 19 23 8 6 13 3 0.0013402 0.0159276 1
hsa-miR-129-2-3p 2597 2503 2661 2472 2400 2422 1627 0.0017505 0.0200339 2
hsa-miR-370 144 135 174 135 118 131 74 0.0018428 0.0203364 2
hsa-miR-190b 298 273 241 233 194 286 365 0.0021923 0.0233596 4
hsa-miR-517c-3p 105 110 110 128 180 176 103 0.0026103 0.026019 4
hsa-miR-519a-3p 105 110 110 128 180 176 103 0.0026103 0.026019 4
hsa-miR-129-5p 1140 1080 1199 1147 986 998 737 0.0029627 0.028176 2
hsa-miR-219-1-3p 12 19 14 5 1 4 4 0.0030091 0.028176 3
hsa-miR-409-5p 93 69 92 88 68 71 38 0.0044917 0.0408215 2
hsa-miR-27a-3p 378 326 477 399 432 412 561 0.0046685 0.0412159 4
hsa-miR-424-5p 123 99 87 125 100 119 180 0.0051385 0.0441053 4
hsa-miR-487a 557 506 618 621 458 513 385 0.0053237 0.0444603 2
hsa-miR-382-5p 49 62 51 56 42 56 18 0.0055054 0.0447675 2
hsa-miR-92b-3p 1334 1357 1335 1490 1530 1658 1981 0.0061121 0.048427 4
hsa-miR-136-5p 1061 1241 1203 1242 1184 1060 803 0.0063022 0.0486845 2
hsa-miR-874 218 157 134 244 206 207 263 0.0064902 0.0489137 4
The values represent the mean of the normalized miRNA counts at each Braak stage for the significant miRNAs. pval: nominal p-value (nbinomGLMTest); padj:
nominal p-value corrected for multiple testing using the BH procedure; Cluster: Fuzzy clustering of the significant miRNAs into four classes.
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the nCounter design used for profiling the two large cohorts of
patients, therefore representing a set of miRNAs meriting further
investigation in the future (Supporting Information Table S4).
From this limited list of 22 miRNAs, miR‐132‐5p and miR‐212‐5p
are found in cluster together with miR‐132‐3p and miR‐212‐3p
on the chromosome 17 of the human genome, between positions
1,953,200 and 1,953,700 (hg19 build). Of importance, the two
miRNAs originating from the pre‐miR‐132 precursor i.e. miR‐
132‐3p and miR‐132‐5p were both found to be downregulated
(padj¼ 8.42E15 and 1.95E10, respectively). Moreover, miR‐
212‐3p and miR‐212‐5p were also downregulated (padj¼ 3.04
E08 and 4.74E07, respectively) (Table 3 and Fig 4C), showing
that not onlymiR‐132‐3p but also the entiremiR‐132/‐212 cluster
was altered in the LOAD prefrontal cortex. Real‐time PCR was
also performed on the 12 prefrontal cortex samples to confirm
alteration of the miR‐132/‐212 cluster, validating the down-
regulation of the four miRNAs (padj¼ 0.0005, ANOVA corrected
by the BH procedure) (Fig 4D).
Because RNA editing can affect target recognition by the
miRNAs, we surveyed adenosine to inosine (A‐I) modification
which is the main type of editing event described in the brain
(Alon et al, 2012; Chiang et al, 2010). We detected 22 of the 29
known (A‐I) RNA editing events in the 12 libraries. TwomiRNAs
were less edited in LOAD than in controls, on the borderline of
significance level (miR‐376c‐3p and miR‐1251 with padj¼ 0.05,
Wilcoxon two‐sample test corrected by BH procedure) (Fig 4E).
In addition, we characterized miR‐132‐3p isoforms in depth and
found decreased mono‐uridylation in LOAD (mean percent of
controls¼ 1.52%of the total reads formiR‐132‐3p,mean percent
of LOAD¼ 0.71%, p¼ 0.004, Wilcoxon two‐sample test),
increased miR‐132‐3p isoform lacking 1 nt at the 3’end (mean
percent of controls¼ 3.76% of the total reads for miR‐132‐3p,
Figure 2. Differential expression of miRNAs in LOAD prefrontal cortex.
A. Hierarchical clustering of deregulated miRNAs across the Braak stages.
Forty one miRNAs were found to differ between any two Braak stages
(p<0.05, nbinomGLMTest after BH adjustment). Hierarchical clustering of
miRNAs was obtained using Spearman’s correlation distance metric and
average linkage. The samples are indicated at the bottom of the heatmap
and miRNAs are found at the right side. Red colour in the colour key
corresponds to high expression and blue colour to low expression values.
The four colours at the top of the heatmap indicate the controls (BR0),
early-stages (BRI and BRII), mid-stages (BRIII and BRIV) and late-stages
(BRV and BRVI) of disease.
B. Time-course analysis of deregulated miRNAs across the Braak stages. The
expression of the 41 deregulated miRNAs was standardized, clustered into
four groups and plotted according to the control (BR0) and the six Braak
stages. Clusters 1, 2 and 3 correspond to downregulated miRNAs during
disease whereas cluster 4 contains the upregulated miRNAs. Down-
regulation was evident between BRII and III stages for the miRNAs found in
cluster 1 whilst a steep decline between BRV and VI characterized the
cluster 2. Cluster 3 contains miRNAs gradually downregulated during
disease. Cluster 4 was the only group corresponding to some upregulated
miRNAs. A biphasic expression profile was observed for clusters 1, 2 and 4
with BRII acting as pivot stage.
C. Expression of cell-type-enriched miRNAs across the Braak stages. The
nCounter normalized counts obtained from the prefrontal cortex samples
for the neuron-enriched and glia-enriched miRNAs were log2 transformed
and plotted against the controls (0) and the six Braak stages (0 to VI).
Neuron-enriched miRNAs are shown in blue, microglial-enriched in green,
astrocyte-enriched in red and oligodendrocyte-enriched miRNAs in purple.
For comparison, the most significantly downregulatedmiRNA i.e. miR-132-
3p is indicated by arrow.
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mean percent of LOAD¼ 8.24%, p¼ 0.002, Wilcoxon two‐
sample test) and decreased miR‐132‐3p isoform lacking 1 nt at
the 5’end (mean percent of controls¼ 2.31% of the total reads
for miR‐132‐3p, mean percent of LOAD¼ 1.77%, p¼ 0.009,
Wilcoxon two‐sample test). Overall, these data show that miR‐
132‐3p, in addition to being downregulated, is also differentially
sequence‐modified in LOAD. Whether such changes in the miR‐
132‐3p sequence are biologically relevant to the disease remains
to be determined.
In situ hybridization of miR‐132‐3p in the human prefrontal
cortex
Given that miR‐132‐3p showed a negative correlation to the
Braak stages (r¼0.63, Pearson’s correlation) and to the
formation of Tau tangles in the prefrontal cortex (r¼0.63,
Pearson’s correlation), ANCOVA analysis was done to determine
whether downregulation of miR‐132‐3p in LOAD could
be explained by additional covariates. The expression of
miR‐132‐3p was related to the Braak stages as expected
(p¼ 1.449E06, ANCOVA F test) but not to sex (p¼ 0.20) nor
to APOE genotype (p¼ 0.50) nor to age (p¼ 0.57) (Fig 5A–C),
therefore supporting a specific role for this miRNA in the disease.
We further determined the expression pattern of miR‐132‐3p
in the prefrontal cortex of LOAD patients and controls using
in situ hybridization. We first investigated whether miR‐132‐3p
was expressed in a particular neuronal population. Virtually all
neurons of the prefrontal cortex (94.3 1.9%, n¼ 8 subjects,
n¼ 98‐219 neurons per subject) (Supporting Information Table
Figure 3. Technical and biological validation of miRNA deregulation in LOAD.
A. Validation of the LOAD hippocampus data. Five controls and five LOAD patients were analyzed to validate the 10miRNAs found to be differentially expressed in
both LOAD hippocampus and prefrontal cortex datasets. Fold changes obtained by real-time PCRwere log2 transformed (Log2FC) and positive values represent
upregulated miRNAs in LOAD whereas negative values correspond to downregulated miRNAs. The miRNAs are indicated at the bottom of the bar plot.
Normalization was done with miR-9-5p.  padj<0.05, ANOVA corrected for multiple testing by the BH procedure. Bars represent standard errors.
B. Validation of the LOAD prefrontal cortex data. Six controls/early-stage and six late-stage samples were selected to confirm expression changes of the 10
miRNAs shown in panel A. The fold changes obtained after real-time PCR between late-stage subjects and controls were log2 transformed. The three
downregulated miRNAs (miR-132-3p, miR-129-5p and miR-136-5p) found to be differentially expressed between the two groups are indicated by  . 
padj<0.05, ANOVA corrected for multiple testing by the BH procedure. Normalization was done with miR-9-5p. Bars represent standard errors.
C. Biological validation in the LOAD temporal gyrus. The temporal gyri of eight healthy subjects and eight LOAD patients were analyzed for the expression of the
10miRNAs found in panels A and B. The real-time PCR fold changes between LOAD and healthy subjects were log2 transformed.  padj<0.05, ANOVA corrected
for multiple testing by the BH procedure. Normalization was achieved using SNORD47. Bars represent standard errors.
D. Deregulation of miRNAs in multiple sclerosis (MS) patients. The active (MS.AL) and chronic (MS.CL) lesions of eight MS patients and the white matter of six
controls (CT) were compared by real-time PCR for the expression of the 10 miRNAs initially found to be deregulated in both LOAD hippocampus and prefrontal
cortex. Normalization was done with miR-9-5p.  padj<0.05 (Post-hoc Tukey’s HSD after ANOVA with p values adjusted for multiple testing by BH correction).
Bars represent standard errors.
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Table 3. MiRNAs called differentially expressed by next‐generation sequencing
miRNA Control LOAD Fold Change log2 Fold Change pval padj
hsa-miR-885-3p 340 75 0.22 2.19 4.30E-20 3.61E-17
hsa-miR-132-3p 10,811 2513 0.23 2.10 2.01E-17 8.42E-15
hsa-miR-132-5p 1315 339 0.26 1.95 6.97E-13 1.95E-10
hsa-miR-3607-3p 3946 576 0.15 2.78 1.08E-12 2.27E-10
hsa-miR-1225-3p 135 27 0.20 2.35 1.04E-11 1.74E-09
hsa-miR-153 4341 12,623 2.91 1.54 1.41E-11 1.97E-09
hsa-miR-323a-3p 6852 2640 0.39 1.38 3.85E-11 4.61E-09
hsa-miR-212-3p 740 215 0.29 1.78 2.89E-10 3.04E-08
hsa-miR-504 1353 540 0.40 1.33 4.24E-10 3.95E-08
hsa-miR-7-1-3p 166 432 2.60 1.38 6.46E-10 5.42E-08
hsa-miR-5701 217 46 0.21 2.25 8.31E-10 6.34E-08
hsa-miR-338-3p 28,741 65,927 2.29 1.20 9.47E-10 6.62E-08
hsa-miR-26b-3p 435 174 0.40 1.33 2.40E-09 1.55E-07
hsa-miR-877-5p 181 60 0.33 1.59 3.05E-09 1.83E-07
hsa-miR-3653 226 51 0.23 2.14 8.27E-09 4.62E-07
hsa-miR-212-5p 197 51 0.26 1.94 9.04E-09 4.74E-07
hsa-miR-150-5p 4314 1951 0.45 1.14 1.05E-08 5.20E-07
hsa-miR-488-3p 535 1212 2.27 1.18 1.93E-08 9.02E-07
hsa-miR-152 83 252 3.03 1.60 3.45E-08 1.52E-06
hsa-miR-539-5p 428 185 0.43 1.21 4.18E-08 1.69E-06
hsa-miR-485-5p 1270 572 0.45 1.15 4.22E-08 1.69E-06
hsa-miR-301a-3p 3613 7532 2.08 1.06 4.69E-08 1.71E-06
hsa-miR-423-3p 13,338 6057 0.45 1.14 4.52E-08 1.71E-06
hsa-miR-340-5p 38,252 19,537 0.51 0.97 6.67E-08 2.33E-06
hsa-miR-323a-5p 66 22 0.33 1.60 8.14E-08 2.73E-06
hsa-miR-18a-5p 81 215 2.65 1.41 1.60E-07 4.98E-06
hsa-miR-330-5p 1235 2588 2.10 1.07 1.60E-07 4.98E-06
hsa-miR-208b 33 90 2.71 1.44 1.68E-07 5.03E-06
hsa-miR-487b 8194 3884 0.47 1.08 2.05E-07 5.93E-06
hsa-miR-32-5p 189 417 2.20 1.14 2.56E-07 6.93E-06
hsa-miR-767-5p 563 253 0.45 1.15 2.53E-07 6.93E-06
hsa-miR-6087 9 2 0.16 2.61 2.69E-07 7.05E-06
hsa-miR-149-5p 25,531 12,021 0.47 1.09 4.27E-07 1.09E-05
hsa-miR-376a-5p 3336 1156 0.35 1.53 5.02E-07 1.24E-05
hsa-miR-142-5p 1367 4387 3.21 1.68 5.28E-07 1.27E-05
hsa-miR-516a-5p 28 76 2.73 1.45 6.19E-07 1.44E-05
hsa-miR-590-3p 125 274 2.19 1.13 9.38E-07 2.13E-05
hsa-miR-138-5p 73,258 30,965 0.42 1.24 9.82E-07 2.17E-05
hsa-miR-744-5p 8825 4298 0.49 1.04 1.05E-06 2.26E-05
hsa-miR-377-3p 231 477 2.07 1.05 1.53E-06 3.21E-05
hsa-miR-222-3p 19,064 10,221 0.54 0.90 1.77E-06 3.62E-05
hsa-let-7d-5p 18,241 9963 0.55 0.87 2.52E-06 5.03E-05
hsa-miR-301b 398 792 1.99 0.99 2.69E-06 5.25E-05
hsa-miR-374b-5p 570 1429 2.51 1.33 3.31E-06 6.31E-05
hsa-miR-194-5p 320 634 1.98 0.98 4.17E-06 7.72E-05
hsa-miR-370 864 397 0.46 1.12 4.23E-06 7.72E-05
hsa-miR-1298 137 60 0.44 1.19 4.67E-06 8.34E-05
hsa-miR-1225-5p 42 12 0.28 1.83 5.25E-06 9.18E-05
hsa-miR-873-3p 531 244 0.46 1.12 5.49E-06 9.40E-05
hsa-miR-708-5p 948 1812 1.91 0.93 5.72E-06 9.59E-05
hsa-miR-6511b-3p 296 146 0.49 1.02 7.77E-06 0.0001
(Continued )
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S5) were positive for miR‐132‐3p, suggesting a broad expression
in neurons throughout this brain area. Interestingly, the miR‐
132‐3p signal highly varied between different cortical layers
(Fig 6A–D). Layer I was negative whilst a low‐to‐moderate
staining intensity was observed in layers II and V. Of note, layers
III/IV and VI contained neurons with highest levels of miR‐132‐
3p. In agreement with the nCounter and real‐time PCR data,
neurons from layers III/IV and VI of a BRVI patient appeared to
contain lower levels of miR‐132‐3p when compared to a BRI
subject (Fig 6C and D). Although a more pronounced down-
regulation of miR‐132‐3p was found in layers III/IV (Fig 6E–H),
the laminar expression pattern was preserved in the BRVI
sample (Fig 6C–D), suggesting that deregulation of miR‐132‐3p
was not limited to a specific neuronal population in a defined
cortical layer. As negative control, the absence of staining was
verified using a scrambled probe (Fig 6I–J).
We also investigated a potential link between downregulation
of miR‐132‐3p and presence of hyper‐phosphorylated Tau in
neuronal cells. In the prefrontal cortex of LOAD patients, Tau
tangles are predominantly localized in layers III/IV and V
neurons (Hof et al, 1990). By combining in situ hybridization
and hyper‐phosphorylated Tau immunostaining, we found
several neurons in the layers III/IV and V of a BRV sample
that were positive for both miR‐132‐3p and hyper‐phosphory-
lated Tau (Fig 7A–G, indicated with arrows). Particularly in
layers III/IV, miR‐132‐3p appeared to be decreased in neurons
positive for hyper‐phosphorylated Tau (Fig 7B, D and F).
However, this expression change was less evident in layer V
Table 3. (Continued)
miRNA Control LOAD Fold Change log2 Fold Change pval padj
hsa-miR-142-3p 202 401 1.98 0.99 7.63E-06 0.0001
hsa-miR-454-3p 838 1583 1.89 0.92 9.10E-06 0.0001
hsa-miR-374a-5p 244 972 3.98 1.99 9.46E-06 0.0001
hsa-miR-769-5p 72,207 40,795 0.56 0.82 9.73E-06 0.0001
hsa-miR-1180 1487 788 0.53 0.92 9.96E-06 0.0001
hsa-miR-6511a-3p 262 130 0.49 1.01 1.02E-05 0.0002
hsa-miR-363-3p 1570 2898 1.85 0.88 1.13E-05 0.0002
hsa-miR-1276 19 6 0.28 1.81 1.21E-05 0.0002
hsa-miR-365a-3p 145 290 1.99 0.99 1.23E-05 0.0002
hsa-miR-186-5p 12,389 21,604 1.74 0.80 1.24E-05 0.0002
hsa-miR-365b-3p 195 380 1.95 0.97 1.30E-05 0.0002
hsa-miR-339-3p 2388 1192 0.50 1.00 1.29E-05 0.0002
hsa-miR-223-3p 324 664 2.05 1.04 1.35E-05 0.0002
hsa-miR-146b-3p 329 168 0.51 0.97 1.45E-05 0.0002
hsa-miR-195-5p 4050 7216 1.78 0.83 1.59E-05 0.0002
hsa-miR-501-3p 195 377 1.93 0.95 1.69E-05 0.0002
hsa-miR-424-5p 175 339 1.94 0.96 1.82E-05 0.0002
hsa-miR-668 668 358 0.54 0.90 2.31E-05 0.0003
hsa-miR-3613-5p 143 278 1.95 0.96 2.42E-05 0.0003
hsa-miR-574-3p 739 1356 1.84 0.88 2.46E-05 0.0003
hsa-miR-511 9 2 0.25 2.00 2.69E-05 0.0003
hsa-miR-6721-5p 8 2 0.24 2.03 3.12E-05 0.0004
hsa-miR-4520a-3p 15 4 0.29 1.80 3.53E-05 0.0004
hsa-miR-409-3p 7499 4337 0.58 0.79 4.07E-05 0.0005
hsa-miR-1185-1-3p 80 32 0.40 1.31 4.93E-05 0.0005
hsa-miR-1307-3p 1827 1025 0.56 0.83 5.14E-05 0.0006
hsa-miR-17-5p 672 1202 1.79 0.84 5.47E-05 0.0006
hsa-miR-423-5p 2621 1491 0.57 0.81 5.54E-05 0.0006
hsa-miR-139-3p 397 216 0.54 0.88 6.15E-05 0.0006
hsa-miR-671-5p 113 56 0.49 1.03 6.48E-05 0.0007
hsa-miR-3613-3p 18 44 2.44 1.28 7.18E-05 0.0007
hsa-miR-148b-3p 1211 4542 3.75 1.91 7.91E-05 0.0008
hsa-miR-16-5p 18,412 30,124 1.64 0.71 8.14E-05 0.0008
hsa-miR-191-3p 142 73 0.51 0.97 8.58E-05 0.0008
Control: normalized counts for the control group; LOAD: normalized counts for the LOAD group; pval: nominal p-value determined by the nbinomTest; padj:
nominal p-value corrected for multiple testing by the BH procedure.
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neurons possibly because of the weaker staining obtained for the
neurons of this cortical layer (Fig 7C, E and G). To establish if
miR‐132‐3p was linked to the Tau pathology at the single‐neuron
level, we quantified miR‐132‐3p in tangle‐positive [AT8(þ)] and
tangle‐negative [AT8()] neurons. Of interest, miR‐132‐3p
levels were significantly lower in AT8(þ) neurons in both
layers III and V, demonstrating a negative correlation between
Tau hyper‐phosphorylation and miR‐132‐3p expression on a
single‐neuron basis (p¼ 0.0003 and 0.0165 for layers III and V
respectively, paired Student’s t‐test) (Fig 7H). Because layer V
neurons are more prone to develop tangles than layer III
neurons, we quantified the expression level of miR‐132‐3p in
those layer V neurons and found it to be significantly lower when
compared to layer III neurons (p< 0.0001, Mann–Whitney U
test) (Fig 7I). Overall, we established a correlation between Tau
hyper‐phosphorylation and miR‐132‐3p expression. Thus it
appears that downregulation of miR‐132‐3p goes together with
Tau hyper‐phosphorylation, a major hallmark of LOAD. The
question remains obviously whether there is also a functional
relationship between the two.
miR‐132‐3p targets FOXO1a, a protein increased in the LOAD
hippocampus
The TargetScan algorithm version 6.2 predicts 407 miR‐132‐3p
targets including several transcripts encoding proteins either
directly involved in LOAD, i.e. MAPT (coding for Tau), or known
regulators of Tau at the post‐transcriptional level, i.e. EP300,
SIRT1 and GSK3B. An additional salient feature is the prediction
of six members of the Forkhead (FOX) transcription factor (TF)
family: FOXA1, FOXN3, FOXO1, FOXO3, FOXP1 and FOXP2.
Note that other target prediction tools have confirmed these
predictions as well (Supporting Information Table S6). Of
interest, when we analyzed published microarray data of
prefrontal cortex samples from the same cohort of 49 patients
analyzed here (Bossers et al, 2010), we found the enrichment of
motifs for the FOX TF family in the promoter region [500 bases
upstream the transcription start site (TSS)] of 882 upregulated
transcripts (Table 4). We found the FOX motif as significantly
enriched (p‐value< 0.001), particularly as the 2nd strongest
enrichedmotif from a large collection of more than 6000 position
weight matrices (Herrmann et al, 2012) (shown in bold in Table
4). As control, we found no enrichment of any FOX motif in the
promoters of 673 downregulated genes. Instead, CREB family
motifs (CREB1 and ATF3) were enriched in this subset
(Supporting Information Table S7). These predictions have
been confirmed using another independent method for motif
discovery (HOMER), and the FOX motifs remained enriched
even within very large upstream sequences of 20 kb (Supporting
Information Table S8).
Of interest, FOXO1a shows a preferential expression in the
murine hippocampus (Hoekman et al, 2006). To determine
whether miR‐132‐3p targets FOXO1a, a luciferase construct
containing 2.5 kb of the 30 Untranslated Region (30UTR) of
human FOXO1a (positions 874‐3385 relative to the start of the
30UTR)was co‐transfected withmiR‐132‐3p in HEK‐293T cells. A
47% decreased of luciferase activity was observed in the
presence of miR‐132‐3p when compared to the co‐transfection of
an irrelevant miRNA (Fig 8A). A double mutant containing two
deletions corresponding to themiR‐132‐3p binding site predicted
by TargetScan (position 2601: 50‐ACUGUUA‐30) and to a non‐
conserved binding site at position 2270 (50‐ACUGUUA‐30) was
less responsive to miR‐132‐3p (p< 0.01, ANOVA corrected by
BH procedure) (Fig 8A). In addition, we also tested the entire
30UTR of EP300, SIRT1 and MAPT. A validated miR‐132‐3p
target, i.e. TJAP1 (Cambronne et al, 2012), was included as
positive control. Highest decreased luciferase activity was
obtained for TJAP1 (65% decreased) followed by MAPT
(57%), SIRT1 (57%) and EP300 (46%) (Fig 8A). Luciferase
constructs containing deletion of the predicted binding sites
were also less responsive to miR‐132‐3p than wild‐type
constructs (p< 0.001 for TJAP1 and SIRT1, p< 0.01 for EP300
and MAPT). Overall, a functional interaction with EP300 and
SIRT1 was confirmed and in addition, two other transcripts
(MAPT and FOXO1a) encoding for additional proteins of the Tau
subnetwork were also found to interact with miR‐132‐3p,
therefore adding evidence that this miRNA could be of relevance
to LOAD. We also showed that FOXO1a was indeed increased in
LOAD patients with low miR‐132‐3p level by comparing its
expression in the hippocampus of 27 subjects including 13
selected controls and 14 LOAD patients. The controls showed
2.73‐fold more miR‐132‐3p than the LOAD subjects (Fig 8B). Of
importance, a 79% increase of FOXO1a was found in the LOAD
group (p¼ 0.002, Welch two‐sample t‐test) (Fig 8C and D).
DISCUSSION
We show that the miR‐132/‐212 cluster is downregulated in
LOAD. In particular, the highest expressed miRNA in this cluster
i.e. miR‐132‐3p is downregulated in three different brain areas
including the hippocampus, the prefrontal cortex and the
temporal gyrus. Downregulation of miR‐132‐3p was consistently
observed irrespective of the three quantitative methods used i.e.
nCounter system, real‐time PCR and deep‐sequencing. A pioneer
study done with a small cohort of subjects previously proposed
miR‐132‐3p to be deregulated in the LOAD hippocampus and
prefrontal cortex (Cogswell et al, 2008) (Supporting Information
Fig S5A and B). While this work was under revision, decreased
miR‐132‐3p was also found in the temporal cortex of a cohort of
29 patients and controls (Wong et al, 2013) and of a smaller
group of eight AD versus eight controls (Hebert et al, 2013),
demonstrating the robustness of our observation. Clearly, our
work, in addition to these three studies, strongly puts miR‐132‐
3p at the centre stage in the study of miRNAs in LOAD.
A major question of our study was to delineate to what extent
miRNA changes accompany disease and disease progression.
We attempted to obtain sufficiently large cohorts of LOAD
patients and controls to address this question in a statistically
sound way. While our work clearly demonstrates that miRNAs
are altered in the brain of LOAD subjects, with 35 and 41
miRNAs significantly deregulated in the hippocampus and
prefrontal cortex, respectively, we reveal that most of the
recorded expression changes are brain area specific, with ten
miRNAs deregulated in both regions. We also provide evidence
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that several of those miRNAs are changed according to the
different Braak stages that characterize the progressive severity
of the disease (Braak & Braak, 1991).
In the past years, profiling of miRNAs in four different brain
regions of LOAD patients was attempted (Cogswell et al, 2008;
Hebert et al, 2008; Nunez‐Iglesias et al, 2010; Wang et al, 2011).
However there is no overlap in the miRNAs identified as altered
(Supporting Information Fig 5C). This clear lack of consensus
could indeed be due to the small number of samples or the
heterogeneity of the brain tissues studied. It should be noted that
the well‐known bias in the different technologies used for
miRNA profiling could be a confounding factor as well (Pritchard
et al, 2012). To tackle these caveats, we used a rather large
number of patients in our study (n¼ 123 cases compared to 57
for the four previous reports combined together). Additionally,
we carefully controlled several inter‐individual covariates such
as age, sex and post‐mortem intervals. We also profiled several
brain areas using different methodologies to reduce bias
introduced by the techniques. We anticipate that, in the future,
larger controlled studies with more subjects will be needed to
fully capture miRNA changes in the LOAD brain. However, a
major limiting factor to overcome is the availability of well‐
documented frozen brain samples.
Apart from brain area specific expression changes and
methodology related considerations, another important ques-
tion is to what extent recorded miRNA differences reflect
disease related processes or more general alterations due to
modifications of cellular composition in the affected brain
regions. For instance, some of the miRNA changes may not
solely be LOAD related but could simply reflect a more
neuronal versus more glia‐like profile. With regard to the
hippocampus samples analyzed, we found increases of
microglial‐enriched miR‐142‐3p, miR‐150‐5p and miR‐223‐3p
in the LOAD group. It is also impossible to exclude that loss of
neurons contributes to decreased miRNA‐132‐3p in those
samples. However, neuronal miRNAs decreased only (and
relatively mildly) at late stages of disease in the prefrontal
cortex, suggesting that neurodegeneration can be an explana-
tion for loss of miRNAs at those late stages only. Several
miRNAs, such as those found in cluster 1, and including miR‐
132‐3p, emerged as being deregulated already at early Braak
stages before the appearance of major neuronal loss. We also
found that many of the downregulated genes in LOAD show a
CREB motif in their promoter regions and given that miR‐132‐
3p is regulated by CREB (Remenyi et al, 2010; Vo et al, 2005), it
is likely that active downregulation of this miRNA is taking
place during disease process. The specific deregulation pattern
of miR‐132‐3p also supports the hypothesis that this miRNA
plays a rather upstream role in the pathogenic cascade of AD.
In agreement, it is of interest to note that miRNA alterations
can be observed rather early in the brain of mouse AD models
as well. For example, the APPswe/PS1DE9 mouse model
displays 37 miRNA alterations already at 3 months of age when
there is no visible neuronal loss (Wang et al, 2009). We
therefore hypothesize that part of the neuronal toxicity caused
by Ab species is mediated, or at least reflected, by changes in
the expression of miRNAs. To support this view, hippocampal
neurons treated with Ab42 showed deregulation of 21 miRNAs
(Schonrock et al, 2010). It remains to be determined whether
miR‐132‐3p expression is also perturbed in the different mouse
models of the disease. Although there was no difference
observed for miR‐132‐3p in the APPswe/PS1DE9 mouse
(Wang et al, 2009), a more recent study showed this miRNA
to be downregulated in the double transgenic APP/PS1 mice at
6 months of age (Wong et al, 2013).
It is also likely that several miRNA changes recorded in our
human brain samples are related to some neuroinflammatory
changes occurring during disease, for instance reflected in the
enrichment of microglial‐specific miRNAs at late stages of
disease i.e. increased miR‐142‐3p, miR‐150‐5p and miR‐223‐3p.
Deregulation of miR‐132‐3p was not however observed in the
small group of MS patients analyzed, in agreement with a
3 Figure 4. Deep‐sequencing of miRNAs in LOAD prefrontal cortex.
A. Downregulated miRNAs in the LOAD prefrontal cortex. Prefrontal cortex of 12 subjects was profiled by next-generation sequencing of miRNAs. The six controls/
early-stages (CT¼BR0.2, BR0.4, BR0.5, BR0.7, BR1.2, BR1.3 samples) and six late-stages (LOAD¼BR5.7, BR6.2, BR6.3, BR6.4, BR6.5, BR6.7 samples) were
compared and heatmap and cluster dendrogram of the 50 most significantly downregulated miRNAs (padj<0.001, nbinomTest after BH adjustment) are
shown. Green¼ controls/early-stages (CT) and brown¼ LOAD patients. Blue: low expression, red: high expression.
B. Upregulated miRNAs in the LOAD prefrontal cortex. Next-generation sequencing of miRNAs of the 12 prefrontal cortex samples shown in panel A revealed 35
upregulated miRNAs (padj<0.001, nbinomTest after BH adjustment). Hiearchical clustering of upregulated miRNAs shows separation of the LOAD group and
controls. Green¼ controls/early-stages (CT) and brown¼ LOAD individuals. Blue: low expression, red: high expression.
C. Normalized counts for the four miRNAs of the miR-132/-212 cluster. Normalized reads corresponding to the miRNAs found in the miR-132/-212 cluster and
obtained from the 12 sequencing libraries are represented on a logarithm scale. Pairwise comparisons of the two arms (5p and 3p) of each miRNA precursor
(pre-miR-132 and pre-miR-212) are shown for the two groups (CT¼ controls/early-stages represented in green and LOAD¼ Alzheimer’s subjects shown in
brown). The expression level of miR-132-3p, miR-132-5p, miR-212-3p and miR-212-5p was, respectively, 4.02, 3.68, 3.22 and 3.61 times lower in the LOAD
when compared to the CT group.  padj<0.001, nbinomTest after BH adjustment.
D. Validation of the four miRNAs in the miR-132/-212 cluster. Real-time PCR for miR-132-3p, miR-132-5p, miR-212-3p and miR-212-5p was performed on the
12 prefrontal cortex samples used in panels A, B and C. Fold changes between the LOAD group and controls were log2 transformed. The log2 fold changes
(Log2FC) obtained for miR-132-3p, miR-132-5p, miR-212-3p and miR-212-5p were 1.67, 1.82, 1.83 and 2.03, respectively.  padj<0.001, ANOVA
corrected by BH procedure.
E. A-I RNA editing events in the LOAD prefrontal cortex. For each miRNA known to be (A-I) edited, the percentage of editing events at each known position was
calculated by dividing the number of reads containing the edited base by the total number of reads corresponding to the miRNA. The six controls/early-stages
(CT) libraries are indicated by blue circles and the six LOAD libraries are represented by red crosses. The number in parenthesis indicates the position on the
miRNA where the editing event occurs, with the first nucleotide at the 50 end of the miRNA being the position 1. The last number at the right side of the
parenthesis corresponds to the p value adjusted for multiple testing using the BH procedure (padj, Wilcoxon two-sample test).
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previous study done with a larger cohort of 30 MS patients/
control subjects (Junker et al, 2009). Thus, alteration of miR‐132‐
3p is not systematically observed in a neuroinflammatory
context although it has been shown that miR‐132‐3p mediates
anti‐inflammatory signalling (Shaked et al, 2009). The targeting
of acetylcholinesterase by miR‐132‐3p may be indeed relevant
for the association of the enzyme activity with amyloid load in
LOAD (Alkalay et al, 2013; Berson et al, 2008), as well as with the
anxiety phenotype and RNA metabolism impairment that are
characteristic of the disease (Berson et al, 2012; Shaltiel et al,
2013).
The deregulation of miR‐132‐3pmight be particularly relevant
to LOAD at several additional levels. For instance, miR‐132‐3p
has been involved in modulating synaptic activity and plasticity
(Wanet et al, 2012). Furthermore, miR‐132‐3p regulates
neuronal outgrowth in response to neurotrophins (Vo et al,
2005), mediates integration of newborn neurons in the adult
hippocampus and dentate gyrus (Luikart et al, 2011; Magill et al,
2010), and shapes synaptic structure (Edbauer et al, 2010) and
plasticity in the visual cortex (Mellios et al, 2011; Tognini et al,
2011). This brings us to the question which molecular targets of
miR‐132‐3p are relevant to LOAD. We analyzed deregulated
transcripts in the LOAD prefrontal cortex samples and identified
several miR‐132‐3p targets including Tau, EP300 and SIRT1, the
latter being post‐translational regulators of Tau (Min et al, 2010)
and FOXO1a. These targets were confirmed using luciferase
assays and we further demonstrated upregulation of FOXO1a
protein in AD hippocampus samples, in agreement with
previous works showing that the FOXO1a transcript is
upregulated in function of the severity of the disease (Blalock
et al, 2004; Gomez Ravetti et al, 2010; Liang et al, 2012), but see
(Bronner et al, 2009). During the revision of the manuscript, a
study proposed miR‐132‐3p to regulate another member of the
FOX family of TFs, i.e. FOXO3a, which is increased in LOAD and
in turn transcriptionally activates pro‐apoptotic genes (Wong
et al, 2013). Thus, evidence increases that FOXs and the FOXOs
in particular, may be regulating important molecular pathways
relevant to LOAD. Intriguingly, we found that not only miR‐132‐
3p regulates FOXs but also many of the predicted miR‐132‐3p
targets show in their promoter regions an enrichment of motifs
for this family of TFs. We estimate the number of such co‐
regulation events mediated bymiR‐132‐3p and the FOXs to be up
to 311 out of 407 (81.3%) predicted targets (Supporting
Information Fig S6).
In conclusion, we provide strong evidence for meaningful
changes in miRNA expression during LOAD and downregulation
of miR‐132‐3p as the most salient feature. Recently, alteration of
miR‐132‐3p expression has also been reported in several other
neurodegenerative diseases including schizophrenia, progres-
sive supranuclear palsy, Huntington’s disease and frontotem-
poral lobar degeneration with TDP‐43 inclusions (FTLD‐TDP)
(Chen‐Plotkin et al, 2012; Johnson et al, 2008; Miller et al, 2012;
Smith et al, 2011). Our work thus clearly indicates that miRNAs
such as miR‐132‐3p deserve further functional exploration to
deepen our understanding of molecular mechanisms driving not
only LOAD but also other neurodegenerative disorders. It is not
unlikely that future studies might reveal part of those common
molecular pathways that are relevant to these conditions.
MATERIALS AND METHODS
Participants and study design
Frozen prefrontal cortex and hippocampus samples were obtained
from the Netherlands Brain Bank (Amsterdam, The Netherlands) and
the MRC London Brain Bank (London, UK), respectively. The prefrontal
Figure 5. Downregulation of miR‐132‐3p is specifically related to disease
progression.
A. Effect of the APOE genotype on miR-132-3p downregulation. The
normalized expression level of miR-132-3p in the prefrontal cortex as
determined by the nCounter system was plotted against the controls (0)
and the six Braak stages (1–6) for which the APOE genotyping was made.
The ANCOVA model was used to assess the effect of the different APOE
genotypes. For the five genotypes present in the 49 samples i.e. APOE 32,
33, 42, 43 and 44, there was no significant difference in the down-
regulation of miR-132-3p (ANCOVA, p¼0.50). Note that APOE42was found
for two patients only.
B. Effect of the age on miR-132-3p downregulation. All the 49 patients were
grouped into bins of 10 years, from 50 to 100 years old. For the five
different bins, we found no significant difference in the downregulation of
miR-132-3p (ANCOVA, p¼0.57).
C. Effect of the sex on miR-132-3p downregulation. For the males and the
females in the cohort of 49 patients analyzed for the expression of miR-
132-3p in the prefrontal cortex, there was no significant difference in the
downregulation of miR-132-3p during disease progression (ANCOVA,
p¼0.20).
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Figure 6. Characterization of miR‐132‐3p expression in LOAD prefrontal cortex.
A‐D. miR-132-3p is expressed in a layer-specific manner. Thionine staining (A) and in situ hybridization for miR-132-3p (B) in consecutive prefrontal cortex
sections of a LOAD patient (BRVI) reveals that miR-132-3p is predominantly expressed in cortical layers III/IV and VI whereas layer I is devoid of signal. In
cortical layers II and V, a low-to-moderate expression of miR-132-3p is seen. The same layer-specific expression pattern is observed in a BRI subject (C and I)
and in another LOAD patient (BRVI) (D). Note the overall decrease of the miR-132-3p signal in the LOAD sample.
E‐H. miR-132-3p is constrained to neuronal structures in the prefrontal cortex. Layer III/IV neurons (E, G) express higher levels of miR-132-3p than layer VI
neurons (F, H). There is apparent overall decrease in the intensity of the signal in LOAD neurons (G, H) compared to the BRI subject (E, F).
I,J. Negative control staining with a scrambled probe. To verify the specificity of the miR-132-3p LNA probe, we hybridized consecutive tissue sections of an
early-stage patient with the miR-132-3p probe (I) or with a scrambled probe (J). The section hybridized with the scrambled probe was completely devoid of
staining whilst intense staining with the miR-132-3p probe was obtained. Scale bars in B, D and J represent 0.25mm. Scale bar in H represents 50mm.
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cortex collection was made of 49 samples covering the six Braak stages
(n¼7 samples for each stage) and of seven additional controls. To avoid
effect of potential confounding factors, the samples were carefully
matched for sex, age, post-mortem interval and pH of the cerebrospinal
fluid (CSF). The 64 hippocampus samples weremade of 23 controls and
41 LOAD cases. All samples were collected according to the legislation
and ethical boards of the two Brain Banks. The samples from the
temporal lobe of LOAD patients were also obtained from the
Figure 7. Tangle formation and downregulation of miR‐132‐3p in LOAD.
A‐G. Downregulation of miR-132-3p colocalizes with hyper-phosphorylated Tau. (A) In situ hybridization of miR-132-3p (red) and immunohistochemical
detection of hyper-phosphorylated Tau (green, AT8 antibody) revealed that hyper-phosphorylated Tau builds up in some miR-132-3p positive neurons of a
BRV patient. Panels B, D, F depict tangle formation in layer III neurons (B: merge, D: AT8, F: miR-132-3p). Panels C, E, G depict tangle formation in layer V
neurons (C: merge, E: AT8, G: miR-132-3p). Arrows denote examples of miR-132-3p and AT8 colocalization. Scale bar in A corresponds to 100mm. Scale bar in
G represents 50mm.
H. miR-132-3p expression is decreased in tangle-bearing neurons. The average fluorescence levels of miR-132-3p in AT8(þ) and AT8() neurons in layers III
and V were quantified for one Braak V individual and two Braak VI subjects. In layer III, the average expression levels are based on 52, 81 and 190 AT8()
neurons and 18, 20 and 35 AT8(þ) neurons, respectively. In layer V, the average expression levels are based on 32, 45 and 145 AT8() neurons and 14, 17 and
41 AT8(þ) neurons, respectively. Note the significant decrease in miR-132-3p levels in AT8(þ) neurons in both cortical layers (p¼0.0003 for layer III and
p¼0.0165 for layer V, paired Student’s t-test).
I. Quantification of miR-132-3p expression levels in layers III and V neurons. The graph represents the miR-132-3p fluorescence intensity of all neurons found
in panel B (layer III) and panel C (layer V). Note that miR-132-3p expression is significantly lower in layer V neurons of this BRV subject (p<0.0001, Mann–
Whitney U test). Red lines indicate median expression levels.
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Netherlands Brain Bank. The MS samples were obtained from the MS
Society Tissue Bank (London, UK). The human study was approved by
the ethical committees of the University of Leuven and by the UZ
Leuven hospital (Reference of the protocol: ML6349).
Total RNA isolation and nCounter hybridization
Prefrontal cortex samples were snap‐frozen in liquid nitrogen and grey
matter was dissected in a cryostat. Frozen hippocampus samples were
directly dissected on dry‐ice. Total RNA was extracted using TRIzol
(Invitrogen, Carlsbad, CA, USA) and purified on mirVana columns
(Ambion, Austin, TX). The active and chronic lesions of six MS patients
and the white matter of normal appearance of eight control subjects
were also dissected and snap‐frozen in TRIzol. The total RNA quality
was assessed on Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). Medium‐throughput profiling of miRNAs was
performed with the nCounter Human miRNA Expression Assay Kit
version 1 (Nanostring Technologies, Seattle,WA, USA). Briefly, 100 ng of
total RNAwas annealed to the nCounter miRNATag reagent, hybridized
to the Reporter CodeSet and run on a nCounter Prep Station (VIB
microarray facility, Leuven).
nCounter analysis
All R packages were downloaded from the Bioconductor (http://www.
bioconductor.org) and the Comprehensive R Archive Network (CRAN)
(http://cran.r‐project.org) repositories. The nCounter definition file from
the nCounter Human miRNA assay Kit version 1 was re‐annotated to
match the human miRNAs found in the most recent version of miRBase
(V19, August 2012). For the hippocampus samples, the nCounter data
were background subtracted using the library NanoStringNorm (version
1.1.14) and a filtering step was applied to keep mean counts >20,
followed by testing for differential expression using the nbinomTest
(library DESeq, version 1.12.0) and corrected for multiple testing using
the BH false discovery rate (FDR) controlling procedure. For the
hierarchical clustering of hippocampus miRNAs, data were clustered
using Spearman’s correlation and average linkage method (library gplots,
version 2.11.0.1).The SVMclassification of the hippocampus samples was
performed using a linear kernel with a gamma¼0.01 and cost¼1
(library e1071, version 1.6‐1). The sensitivity or true positive rate (TPR)
was defined as TPR¼ True Positive/(True Positiveþ False Negative). The
specificity or true negative rate (TNR) was calculated as followed:
TNR¼ True Negative/(True Negativeþ False Positive). The ROC was
determined using the library ROCR (version 1.0‐5).
The nCounter data obtained from the prefrontal cortex samples
were similarly processed except that filtering was set to keep >10
mean counts and differential expression between any two Braak stages
was assessed using ANOVADEV (fitNbinomGLMs in the library DESeq).
p‐values were corrected for multiple testing using the BH procedure.
Hierarchical clustering of prefrontal cortex miRNAs was performed
Table 4. Enrichment of TF binding sites in the promoter of genes upregulated between BRI and BRVI stages
Rank Motif id Z‐score Transcription factor Targets
1 yetfasco-1638 4.33 NFYC,POLE4 46
2 yetfasco‐1467 3.89 FOXP1,FOXP4,FOXP3,FOXJ1,FOXP2,FOXO1 69
3 jaspar-MA0012.1 3.78 NA 172
4 jaspar-PB0141.1 3.76 IRF9 87
5 jaspar-PB0116.1 3.76 ELF3 51
6 jaspar‐PB0119.1 3.74 FOXA2,NANOG,NANOGP1 84
7 transfac_pro-M00091 3.60 NA 44
8 transfac_pro-M01281 3.53 NFATC2,NFATC4 46
9 flyfactorsurvey-br-Z3_FlyReg_FBgn0000210 3.49 NA 34
10 transfac_pro-M00093 3.48 NA 72
11 transfac_pro-M00160 3.46 SRY,SOX5,SOX9,NANOG,SOX7,NANOGP1 72
12 yetfasco‐382 3.35 FOXP1,FOXP4,FOXP3,FOXP2,FOXJ1,FOXF2,FOXO3 FOXO4,FOXO1,FOXJ3,SRF,FOXK1 31
13 jaspar-PB0186.1 3.30 PAX4,ELF3,TFAP2E 136
14 transfac_pro‐M01599 3.26 FOXP3,FOXF2,FOXP4,FOXP2,FOXJ3 40
15 transfac_pro‐M00477 3.23 FOXO3,FOXO4,FOXO1,FOXF2,FOXK1,FOXP2,FOXP1FOXP4,FOXJ3 31
16 jaspar-MA0013.1 3.17 NA 55
17 transfac_pro-M00094 3.15 NA 53
18 transfac_pro‐M01137 3.13 FOXO3,FOXO4,FOXP1,FOXP4,FOXP2,FOXK1 81
19 transfac_pro-M01010 3.11 HMGA2,HMGA1 52
20 transfac_pro-M00935 3.07 NFATC4,NFATC2,NFATC1,NFATC3 41
21 transfac_pro‐M00475 3.07 FOXO1,FOXO4,FOXO3,FOXF2,FOXP1,FOXP2,FOXP4 94
FOXJ3,FOXK1
22 transfac_pro-M00456 3.05 BPTF 140
23 yetfasco‐570 3.03 FOXO4,FOXO1 47
24 jaspar‐MA0317.1 3.02 FOXO4,FOXO1 48
There were 882 genes upregulated between BRI and BRVI stages. Motif ids were obtained from the JASPAR, TRANSFAC and YeTFaSCo database. Transcription
Factor: TF predicted to bind to the motif; NA: motifs not annotated; Targets: number of upregulated genes containing the motif inside 500 bp upstream the
transcription start site.
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using Spearman’s correlation and average linkage method (library
gplots). Fuzzy clustering of significantly deregulated miRNAs (p<0.05,
ANOVADEV corrected by the BH procedure) into four clusters was made
by using 1.1 degrees of fuzziness (library Mfuzz, version 2.18.0).
Additional data analysis was done for the prefrontal cortex dataset
using the GLM implemented in edgeR (version 3.2.3) and the Voom
transformation found in Limma (version 3.16.5).
Real‐time PCR
To validate miRNA changes, total RNA of five controls and five LOAD
hippocampus samples was reverse transcribed using the miRCURY LNA
Universal RT kit (Exiqon, Denmark). The reverse transcription mix
contained 4ml of total RNA (200ng), 4ml of 5 reaction buffer, 2ml of
enzyme mix and 10ml of water. The reactions were incubated at 42°C
for 1 h followed by inactivation at 95°C for 5min. The samples were
diluted 20 and 4ml of diluted product was assessed in a PCR reaction
mix containing 5ml of SYBR Green master mix and 1ml of miRNA
specific primers (Exiqon). Real‐time PCR was performed on 96‐well
plates using the LightCycler 480 Real‐Time PCR system (Roche,
Indianapolis, IN, USA). The PCR conditions were 95°C, 10min followed
by 45 cycles at 95°C, 10 s and 60°C, 1min. The crossing point (Cp) was
determined by using the second derivative method and data were
normalized with miR‐9‐5p. Fold changes and statistical significance
were calculated using one‐way ANOVA. Validation of the 12 prefrontal
cortex samples and analysis of the 14 MS samples were performed
similarly using miR‐9‐5p as normalizer and ANOVA followed by post-
hoc Tukey’s HSD for the comparison of multiple MS groups. Correction
for multiple testing was done using the BH procedure. The validation of
the temporal lobe of eight LOAD patients and eight controls was done
after extracting the RNA using the miRNeasy Mini Kit (Qiagen, Venlo,
The Netherlands). The cDNA was prepared using the qScript microRNA
cDNA Synthesis Kit (Quanta BioSciences, Gaithersburg, MD, USA) and
semi‐quantitative PCR was performed using Quanta miR primers and
PerfeCta SYBR Green FastMix, Low ROX (Quanta BioSciences). Light
emission was measured using the Bio‐Rad CFX96TM Real‐Time PCR
Detection System (Bio‐Rad). Normalization was achieved using
SNORD47.
Deep‐sequencing of miRNAs
Deep‐sequencing of miRNAs from 12 prefrontal cortex samples was
performed after reverse transcription of the total RNA and ligation of 50
and 30 adaptors using the TruSeq Small RNA Sample Preparation Kit
(Illumina, San Diego, CA, USA). After gel purification, the PCR products
were sequenced for 35 cycles on an Illumina HiSeq 2000 system (CME
Genomics Core, UZ Leuven). The adaptor (50‐TGGAATTCTCGGGTGC-
CAAGG‐30) was trimmed from the raw sequencing reads using Flicker
3.0 (Illumina) and manual filtering steps were performed to remove
low quality reads and reads containing ambiguous nucleotides. Reads
longer than 15 nucleotides were mapped to the hg19 build genome
using the short‐read aligner Bowtie2 (version 2.0.2) and allowing one
Figure 8. Identification of miR‐132 targets of relevance to LOAD.
A. In vitro validation of miR-132-target pairs. Luciferase assays were
performed to determine functional interaction between miR-132-3p and
the 30UTR of predicted targets found in the Tau subnetwork including
EP300, SIRT1, MAPT (Tau) and FOXO1. TJAP1was described as in vivo target
of miR-132-3p and used as positive control. Reporter plasmids containing
the different 30UTRs were transiently co-transfected with the miRNA
negative control 1 (grey bars arbitrary set at 100 for each plasmid) or miR-
132-3p (green bars). Red bars indicate data obtained with plasmids
containing deletion of the miR-132-3p binding site(s). Data represent
mean with SEM of at least three independent transfections.  p<0.001
and  p<0.01, ANOVA corrected for multiple testing by BH procedure.
B. Expression of miR-132-3p in 27 selected subjects. Boxplots represent the
level of miR-132-3p in the hippocampus of 13 selected controls (CT) and
14 selected LOAD. Normalized counts for miR-132-3p were obtained from
the nCounter experiment. There was no overlap between the two groups,
with the controls showing higher miR-132-3p expression than the LOAD
group. Red circles indicate the different samples.
C. Quantification of FOXO1a expression in the 27 selected subjects. Western-
blot analysis of FOXO1a in the hippocampus of 13 controls (CT) and 14
LOAD subjects was done to assess difference in protein expression between
the two groups from panel B. Normalization was done with GAPDH. Red
circles indicate the 27 different samples.  p<0.01, Welch two sample t-
test.
D. FOXO1a expression in the hippocampus of 14 selected subjects. Difference
in FOXO1a protein expression is illustrated for seven controls and seven
LOAD subjects. Loading control done with GAPDH is shown below FOXO1a.
Vertical dashed line separates the two groups.
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mismatch. Quantification of mature miRNAs was made using the
HTSeq‐counts (version 0.5.3p9) taking into account the strand
orientation and guided with the mature miRNAs from the miRBase
v19 gff3 annotation file. After weighting by one, the low counts were
discarded (minimum 30 counts over the 12 samples). Differential
expression was done using DESeq (version 1.6.1) after top geometric
mean normalization on the 75 top expressed miRNAs (Waggott et al,
2012).
To examine miRNA editing events, we searched for previously
reported A‐G changes corresponding to A‐I editing events. The editing
frequency was calculated as the number of reads containing the A‐G
modification divided by the total number of reads corresponding to the
same miRNA. Statistical difference between the two groups was
assessed by using the Wilcoxon two‐sample test followed by BH
correction. The data obtained from the 12 libraries have been
submitted to the GEO database under accession number GSE48552.
Detection of miR‐132‐3p by in situ hybridization
Chimeric 20‐O‐methyl/LNA oligoribonucleotide probes were obtained
from Ribotask (Odense, Denmark). The sequence of the miR‐132‐3p
LNA probe was:
50‐FAM‐lCmGmAlCmCmAlTmGmGlCmUmGlTmAmGlAmCmUlGmU-
mUlA‐30 with FAM denoting a fluorescein tag, l a locked nucleic acid
(LNA) and m a 20‐O‐methyl modified ribonucleic acid. The sequence of
the scrambled probewas 50‐FAM‐lAmCmUlTmAmClGmCmUlAmGmUlG-
mUmGlGmA‐mAlCmGmClT‐30 . In situ hybridization was performed as
previously described (Shan et al, 2012). Briefly, 6mm‐thick formalin‐
fixed, paraffin‐embedded sections were de‐paraffinized and boiled for
10min in citrate buffer (pH 6.0). After de‐proteinization and de‐
lipidation, sections were prehybridized for 1 h in hybridization mix
[10mM HEPES (pH 7.5), 5 Denhardt’s solution, 50% formamide,
600mMNaCl and 1mMEDTA]. Hybridizationwas performed for 90min
at 58°C with either 25nM of antisense or scrambled LNA probe diluted
in hybridization mix. Sections were subsequently washed for 5min each
in 5SSC (saline‐sodium citrate buffer), 2SSC, 0.2SSC (all at 58°C)
and 5min in PBS. For detection of the LNA probe, sections were blocked
for 1 h and incubated overnight at 4°C with rabbit anti‐fluorescein
coupled to alkaline phosphatase (Roche, 1:3000). The sections were
developed with NBT/BCIP colour substrate and the colour reaction was
stopped in distilled water.
Co‐detection of miR‐132‐3p and hyper‐phosphorylated Tau
Hybridization of the miR‐132‐3p LNA probe was performed as
described above. For immunological detection of miR‐132‐3p and
hyper‐phosphorylated Tau, the sections were washed for 25min in
TBS and incubated with rabbit anti‐fluorescein coupled to alkaline
phosphatase (1:3000) and mouse anti‐human PHF‐Tau clone AT8
(Perbio Science, 1:800) in PBS/0.5% BSA for 1 h at RT, followed
by overnight incubation at 4°C. Sections were washed 25min in
TBS and incubated for 1 h with donkey anti‐mouse DyLight488 (Bio‐
Connect, 1:1400). The auto‐fluorescence was blocked by incubating
25min in TBS, 7min in 70% ethanol/0.5% Sudan Black, 25min
in TBS and 25min in 0.05M Tris‐HCl (pH 8.2). The colour reaction
was performed with Fast Red TR/Napthol AS‐MX (Sigma–Aldrich
Chemie, The Netherlands) and stopped in distilled water. All sections
were coverslipped with Mowiol.
Quantification of miR‐132‐3p levels
The images were acquired with an Axioplan microscope at 10
magnification (Carl Zeiss) and analyzed using the Image Pro Plus
software (Media Cybernetics, Bethesda, MD, USA). For the quantifica-
tion of the miR‐132‐3p fluorescence levels in AT8(þ) and AT8()
neurons, cortical layers III and V were analyzed separately. Briefly, a
stretch of layer III or V was manually outlined and fields covering 50%
of the outline were randomly selected. Per field, miR‐132‐3p
expression levels were estimated by measuring the average fluores-
cence intensity in a circle with a diameter of eight pixels (equivalent to
51mm2) placed in the soma of all miR‐132‐3p positive neurons.
The paper explained
PROBLEM:
Alzheimer’s disease (AD) is the most common form of dementia.
While most of ongoing research is focused on the contribution of
Tau and the amyloid b- (Ab) protein, other molecular pathways
are involved in the neurodegenerative process underlying the
disorder. Recently, microRNAs have been recognized as impor-
tant regulators of gene expression and their aberrant expression
could lead to perturbation of cellular homeostasis and ultimately
to neurodegeneration. However, little is known about the global
expression pattern of microRNAs in the brain of patients and the
molecular networks potentially regulated by such microRNAs.
Moreover, reproducibility of recorded alterations is amajor issue.
RESULTS:
In our study, we found deregulation of a small subset of
microRNAs in the hippocampus and prefrontal cortex of AD
patients. We established miR-132-3p as being the most altered
microRNA during disease. Downregulation of miR-132-3p in
neuronal cells was inversely correlated with the appearance of
the hyper-phosphorylated form of Tau. Additional analysis of
miR-132-3p targets points to the FOX transcription factors (TFs)
as regulated by and sharing a common subset of targets with this
microRNA.
IMPACT:
Our results provide the first large scale analysis of microRNAs
altered in AD. When the disease worsens, neuronal cells show
lower amount of miR-132-3p and hyper-phosphorylated Tau
accumulates in these cells, therefore establishing the down-
regulation of miR-132-3p as a new marker of AD and potentially
other neurodegenerative disorders.
Research Articlewww.embomolmed.org
Pierre Lau et al.
EMBO Mol Med (2013) 5, 1–22  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 19
Furthermore, each neuron was classified as AT8(þ) or AT8(). Finally,
the average miR‐132‐3p intensity of AT8(þ) and AT8() neurons was
calculated separately for layers III and V. Statistical significance was
determined with a paired Student’s t‐test. For the comparison of miR‐
132‐3p levels between cortical layers, the miR‐132‐3p expression
levels were estimated by measuring the average fluorescence intensity
in miR‐132‐3p positive neurons as described above.
Regulatory analysis
Differentially expressed transcripts between BRI and BRVI stages were
determined with Limma. Detection of enriched TFs on protein coding
genes was performed on 500 bp promoter sequences of 882
upregulated genes between BRVI and BRI stages (FDR<0.05) with
the parameters for a motif collection of 6683 position weight matrices
using an empirical p‐value (Herrmann et al, 2012). The results were
confirmed using Hypergeometric Optimization of Motif EnRichment
(HOMER) Suite version 4.2 (Heinz et al, 2010). The program findMotifs.
pl was run on a regulatory region of 20 kb centred around the TSS and
all the other parameters were used as default to detect the significant
motifs from their in‐house motif library (1865 motifs).
Luciferase assays
The 30UTRs were cloned by PCR using the Phusion enzyme kit (NEB,
Ipswich, MA, USA) and human brain cDNA as template (Clontech,
Mountain View, CA, USA). For MAPTcloning, PCR was performed using a
201 kb P1‐derived artificial chromosome (PAC) containing the human
MAPTgene (Poorkaj et al, 2001).The sequences of the PCR primers used
for cloning can be found in Supporting Information Table S9. Briefly,
PCR products were cut with Asc I and Xho I restriction enzymes and
cloned into the psicheck3 vector, a derivative of the psicheck2 plasmid
(Promega, Madison, WI, USA) containing an Asc I site inserted into the
multiple cloning site (MCS). All plasmids were verified by dideoxy DNA
sequencing. For luciferase assays, HEK‐293T cells were grown on 24‐
well plates and transfected with 200ng of reporter plasmid and
20pmol of miR‐132‐3p miRIDIANmiRNAmimic (Dharmacon, Boulder,
CO, USA) or miRIDIAN miRNA negative control 1 (Dharmacon) using
Lipofectamine 2000 (Invitrogen). After 48 h, cells were processed using
the Dual Luciferase Assay kit (Promega) and analyzed using an Envision
luminescent plate reader (Perkin‐Elmer, Waltham, MA, USA). For each
reporter construct, renilla activity was normalized according to that of
firefly. Normalized activity after co‐transfection of miR‐132‐3p with a
reporter construct was expressed as relative to that obtained after co‐
transfecting the same plasmid with miRNA negative control 1.
Statistical significance was determined using ANOVA with correction
for multiple testing by the BH procedure.
Western‐blot
Primary antibody against FOXO1a (C29H4) was from Cell Signalling
Technology (Danvers, MA, USA). Primary antibody against GAPDH (5G4)
was obtained from Hy‐Test (Turku, Finland). Protein extracts from
human hippocampus were obtained after cell lysis in RIPA buffer and
sonication. After determining the protein concentration, twenty
micrograms of proteins were resolved on Bis‐Tris gels (Invitrogen)
and transferred onto nylonmembranes. After blocking with 5% non‐fat
milk in TBS/Tween‐20, blots were incubated overnight with the
different primary antibodies. After several consecutive washes in
TBS/Tween‐20, membranes were incubated with anti‐rabbit‐HRP
conjugated secondary antibody (for FOXO1a) or anti‐mouse‐HRP
secondary antibody (for GAPDH) and developed using the Western
Lighting Plus‐ECL chemiluminescent reagent (Perkin‐Elmer).
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